{"product_id":"proteogenix-anti-cd28-biosimilar-anti-cd28tp44-mab-research-grade","title":"Anti-CD28 Biosimilar – Anti-CD28(Tp44) mAb – Research Grade","description":"\u003ch3\u003eIntroduction\u003c\/h3\u003e \u003cp\u003eAnti-CD28 Biosimilar – Anti-CD28(Tp44) mAb – Research Grade is a monoclonal antibody that targets the CD28 protein, a co-stimulatory molecule found on the surface of T cells. This biosimilar is a highly specific and potent therapeutic agent that has been extensively studied for its potential use in various immune-related disorders.\u003c\/p\u003e \u003ch3\u003eStructure\u003c\/h3\u003e \u003cp\u003eAnti-CD28(Tp44) mAb is a recombinant antibody that is produced using advanced biotechnology techniques. It is a fully humanized IgG1 antibody, meaning it is derived from human cells and has a structure similar to natural antibodies found in the body. This structure allows for high binding affinity and specificity to the CD28 protein.\u003c\/p\u003e \u003cp\u003eThe antibody consists of two heavy chains and two light chains, each with a variable region that recognizes the CD28 protein and a constant region that mediates effector functions. The variable regions are responsible for the specificity of the antibody, while the constant regions play a role in immune response activation and regulation.\u003c\/p\u003e \u003ch3\u003eActivity\u003c\/h3\u003e \u003cp\u003eThe main function of Anti-CD28(Tp44) mAb is to block the interaction between CD28 and its ligands, CD80 and CD86, on antigen-presenting cells. This interaction is crucial for T cell activation and proliferation, and by inhibiting it, the antibody can modulate the immune response.\u003c\/p\u003e \u003cp\u003eIn addition to blocking CD28, Anti-CD28(Tp44) mAb also activates the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) pathway, which further suppresses T cell activation. This dual mechanism of action makes the antibody a potent immunosuppressive agent.\u003c\/p\u003e \u003ch3\u003eApplication\u003c\/h3\u003e \u003cp\u003eAnti-CD28(Tp44) mAb has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various immune-related disorders. Some of the potential applications of this biosimilar include:\u003c\/p\u003e \u003cp\u003e1. Organ transplantation: The antibody has shown to be effective in preventing organ rejection in animal models by suppressing T cell activation. Clinical trials are currently underway to evaluate its use in human organ transplant recipients.\u003c\/p\u003e \u003cp\u003e2. Autoimmune diseases: The dysregulation of T cell activation is a key feature of autoimmune diseases. Anti-CD28(Tp44) mAb has the potential to modulate this process and has shown promising results in preclinical studies for diseases such as rheumatoid arthritis and multiple sclerosis.\u003c\/p\u003e \u003cp\u003e3.\u003c\/p\u003e \u003cp\u003eCancer immunotherapy: T cells play a crucial role in the body’s immune response against cancer cells. By inhibiting T cell activation, Anti-CD28(Tp44) mAb can potentially enhance the anti-tumor immune response. Clinical trials are currently investigating its use in combination with other cancer treatments.\u003c\/p\u003e \u003cp\u003e4. Allergic diseases: T cell-mediated inflammation is a hallmark of allergic diseases such as asthma and eczema. Anti-CD28(Tp44) mAb has shown to be effective in reducing inflammation and symptoms in preclinical studies and is being evaluated in clinical trials for these conditions.\u003c\/p\u003e \u003ch3\u003eConclusion\u003c\/h3\u003e \u003cp\u003eAnti-CD28 Biosimilar – Anti-CD28(Tp44) mAb – Research Grade is a highly specific and potent therapeutic agent that targets the CD28 protein on T cells. Its dual mechanism of action of blocking CD28 and activating CTLA-4 makes it a promising treatment option for various immune-related disorders. Ongoing clinical trials will provide further insight into its efficacy and safety, and it has the potential to become a valuable addition to the current treatment options for these diseases.\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PX-TA1625. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: CD28 Biosimilar – Anti-CD28(Tp44) mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: \u0026gt;85%; Buffer: PBS buffer pH7.5; Applications: ELISA, WB.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PX-TA1625.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357806666068,"sku":"ABM134421-1","price":111.2,"currency_code":"GBP","in_stock":true},{"title":"100ug","offer_id":57357806698836,"sku":"ABM134421-2","price":175.2,"currency_code":"GBP","in_stock":true},{"title":"1mg","offer_id":57357806731604,"sku":"ABM134421-3","price":375.2,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/Primaryantibodies-CCt9H6Tc_fad42c59-7beb-41a7-9ea4-04935ac9484d.svg?v=1790891138","url":"https:\/\/www.abmium.com\/es\/products\/proteogenix-anti-cd28-biosimilar-anti-cd28tp44-mab-research-grade","provider":"ABMIUM","version":"1.0","type":"link"}